| LP441733-5 | 3-Methylglutaconate aciduria multigene analysis | COMPONENT | 1 |
| LP441734-3 | Acute myeloid Leukemia multigene analysis | COMPONENT | 1 |
| LP441735-0 | Acute porphyria multigene analysis | COMPONENT | 1 |
| LP441736-8 | Cholestasis multigene analysis | COMPONENT | 1 |
| LP441737-6 | Glycosylation congenital disorders multigene analysis | COMPONENT | 1 |
| LP441738-4 | Congenital lactic acidosis multigene analysis | COMPONENT | 1 |
| LP441739-2 | Fatty acid oxidation multigene analysis | COMPONENT | 1 |
| LP441740-0 | Glutarate aciduria 2 multigene analysis | COMPONENT | 1 |
| LP441741-8 | Maple syrup urine disease multigene analysis | COMPONENT | 1 |
| LP441742-6 | Methylmalonate aciduria multigene analysis | COMPONENT | 1 |
| LP441744-2 | Methylmalonate aciduria-propionic aciduria multigene analysis | COMPONENT | 1 |
| LP441746-7 | Neuronal ceroid lipofuscinosis multigene analysis | COMPONENT | 1 |
| LP441747-5 | Porphyria multigene analysis | COMPONENT | 1 |
| LP441750-9 | Hereditary erythrocytosis multigene analysis | COMPONENT | 1 |
| LP441752-5 | Blasts.CD45/100 cells | COMPONENT | 3 |
| LP441753-3 | Blasts.CD45 | COMPONENT | |
| LP441758-2 | Cells.CD26+CD3+/Cells | COMPONENT | 1 |
| LP441759-0 | Cells.CD26+CD3+ | COMPONENT | |
| LP441760-8 | Blasts.HLA-DR+/Cells | COMPONENT | 3 |
| LP441761-6 | Blasts.HLA-DR+ | COMPONENT | |
| LP441762-4 | T-ALL minimal residual disease detection | COMPONENT | 2 |
| LP441763-2 | B-ALL minimal residual disease detection | COMPONENT | 2 |
| LP441765-7 | Blasts.CD45+/Cells | COMPONENT | |
| LP441766-5 | Blasts.CD45+ | COMPONENT | |
| LP441767-3 | Cells.CD20+/Cells.CD19+ | COMPONENT | 2 |
| LP441768-1 | Cells.CD20+ | COMPONENT | |
| LP441769-9 | Cells.CD19+ | DIVISORS | |
| LP441770-7 | Cells.CD3+CD19- (T cells)/Lymphocytes | COMPONENT | 3 |
| LP441773-1 | T Lymphocytes.CD3+CD19-/Cells | COMPONENT | 3 |
| LP441774-9 | CLL minimal residual disease detection | COMPONENT | 2 |
| LP441775-6 | Immunophenotyping | COMPONENT | |
| LP441781-4 | Bacterial Carbapenem resistance blaNDM-7 gene | COMPONENT | 1 |
| LP441783-0 | Clostridioides difficile presence and susceptibility | COMPONENT | 1 |
| LP441784-8 | Tumor area infiltrated with PD-L1 expressing immune cells/Total tumor area | COMPONENT | 1 |
| LP441785-5 | Tumor area infiltrated with PD-L1 expressing immune cells | COMPONENT | |
| LP441787-1 | Worker | METHOD | 1 |
| LP441796-2 | Bladder and Prostate cancer multigene analysis | COMPONENT | 1 |
| LP441798-8 | Endometrial carcinoma multigene analysis | COMPONENT | 1 |
| LP441799-6 | MYOD1 targeted gene mutation analysis | COMPONENT | 1 |
| LP441800-2 | Renal cell carcinoma fibromyomatous stroma multigene analysis | COMPONENT | 1 |
| LP441801-0 | Gynecological carcinoma multigene analysis | COMPONENT | 1 |
| LP441802-8 | Renal cell carcinoma multigene analysis | COMPONENT | 1 |
| LP441804-4 | Ovarian, fallopian tube and peritoneal carcinoma multigene analysis | COMPONENT | 1 |
| LP441813-5 | Lived environment national rank | COMPONENT | 1 |
| LP441814-3 | Lived environment state rank | COMPONENT | 1 |
| LP441815-0 | Lived environment risk | COMPONENT | 1 |
| LP441816-8 | Lived environment estimated risk | COMPONENT | 1 |
| LP441817-6 | Lived environment annual mean of particulate matter concentration | COMPONENT | 1 |
| LP441818-4 | Healthcare-medically underserved areas- census tract | COMPONENT | 1 |
| LP441819-2 | Healthcare medically underserved areas county | COMPONENT | 1 |